Browsing Tag
Kesimpta
4 posts
Novartis profit plunges 70% after $1.9bn drug impairment despite stronger core earnings
Novartis reported $14.52 billion in quarterly sales and an 11% increase in core operating profit, but statutory net income declined 70% following a major impairment related to its investigational medicine del-desiran. Strong oncology and immunology sales are helping offset generic competition, while the drug pipeline presents new financial uncertainties.
Novartis gains another potential MS growth engine after remibrutinib beats teriflunomide in two Phase III trials
Novartis shares surge after remibrutinib wins two Phase III MS trials, opening another potential growth opportunity alongside Kesimpta.
Novartis achieves 22% rise in core operating income, driven by innovative medicines
Novartis has reported a stellar performance for the fourth quarter of 2024, showcasing impressive growth across its core…
Novartis announces promising long-term data on Kesimpta for relapsing multiple sclerosis
In a significant revelation, Novartis Pharmaceuticals Corporation has announced the latest findings from the ALITHIOS open-label extension study.…